Intervention

AZD2811

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions3

Lead sponsors shown2

Clinical trials

3 shown

Study of AZD2811 + Durvalumab in ES-SCLCNCT04745689 · 2021-02-23

ACTIVE_NOT_RECRUITING

AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]NCT03366675 · 2017-12-01

TERMINATED

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.NCT02579226 · 2015-10-28

COMPLETED

Common conditions

Advanced Solid Tumours1 Small Cell Lung Cancer1 Small-Cell Lung Cancer1

Leading sponsors

AstraZeneca 2 Samsung Medical Center 1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

TERMINATED1

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.